BeOne Medicines (BEIGF) Net Income towards Common Stockholders (2015 - 2026)

BeOne Medicines (BEIGF) has reported Net Income towards Common Stockholders for 12 consecutive years, with $237.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 151.28% year-over-year to $237.0 million in Q2 2026; TTM through Jun 2026 was $655.7 million, a 469.12% increase from a year earlier, with the FY2025 full-year figure at $286.9 million, up 144.5% from the prior year.
• Net Income towards Common Stockholders was $237.0 million for Q2 2026 at BeOne Medicines, up from $227.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $237.0 million in Q2 2026 and troughed at -$565.7 million in Q2 2022.
• A 5-year average of -$154.4 million and a median of -$136.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 754.48% in 2022 and jumped 17802.13% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$445.3 million in 2022, then gained by 17.47% to -$367.6 million in 2023, then soared by 58.68% to -$151.9 million in 2024, then soared by 143.79% to $66.5 million in 2025, then jumped by 256.39% to $237.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $237.0 million (Q2 2026), $227.4 million (Q1 2026), and $66.5 million (Q4 2025), per Business Quant data.